Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07621809 · ClinicalTrials.gov registry record · Phase 3
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 570
- Enrollment target
NCT07621809 is a Phase 3 study that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 570 participants.
The verdict
NCT07621809, a Phase 3 study, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 570 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the efficacy and safety of ianalumab (VAY736) 300 mg administered subcutaneously (s.c.) monthly for 52 weeks in adult participants with Sjögren's disease who have high symptom burden.
Interventions
- DRUG Placebo
- DRUG VAY736
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 570 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2033-08-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07621809
The ClinicalTrials.gov registry entry for NCT07621809 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 570 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07621809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07621809 about?
NCT07621809 is a clinical study titled "Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden". The purpose of this study is to demonstrate the efficacy and safety of ianalumab (VAY736) 300 mg administered subcutaneously (s.c.) monthly for 52 weeks in adult participants with Sjögren's disease who have high symptom burden.
What is the current status of trial NCT07621809?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 570 participants. The study started on 2026-07-15. Estimated completion is 2033-08-12.
What interventions are being tested in trial NCT07621809?
The interventions under investigation include: Placebo (DRUG), VAY736 (DRUG).
Who is sponsoring clinical trial NCT07621809?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.